Skip to main content

Advertisement

SpringerLink
Log in

Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

The 2011 St. Gallen Consensus Statement advocated using histological grade (HG) as a proliferation marker of breast cancer (BC) if reliable Ki67 labeling index (Ki67-LI) assessment is not available. However, it has been difficult to evaluate tumor aggressiveness in case of HG2.

Methods

A total of 259 cases of BC were assessed for HG, Ki67-LI and other clinicopathological features. The cut point for Ki67-LI was interpreted as low and high using a 14 % threshold.

Results

The average age at diagnosis was 58.2 years (range 28–86); 64.9 % of the patients were postmenopausal. Of the 259 cases, 151 were stage I, 78 were stage II, 29 were stage III, and 1 was stage IV. The subtypes based on immunohistochemical staining were 60 cases of luminal A (LA) type (23.2 %), 37 cases of luminal B (LB) (HER2−) type (14.3 %), 91 cases of LB (HER2+) type (35.1 %), 40 cases of human epidermal growth factor receptor 2 (HER2) type (15.4 %) and 31 cases of triple negative (TN) type (12 %). HG was 1 (89 cases, 34.4 %), 2 (117 cases, 45.2 %) and 3 (53 cases, 20.5 %). High Ki67-LI cases were observed in HG1 (37.1 %), HG2 (56.4 %) and HG3 (96.2 %). Especially in cases of HG2, high Ki67-LI cases were observed in 0 % of LA type, 100 % of LB (HER2−) type, 71.2 % of LB (HER2+) type, 68.8 % of HER2 type and 40.0 % of TN type. The average Ki67-LI was 6.0 ± 3.8 (LA type), 31.4 ± 15.7 [LB (HER2−) type], 20.2 ± 14.8 [LB (HER2+) type], 32.7 ± 21.9 (HER2 type) and 55.7 ± 32.2 (TN type). All LA-type cases and 66.7 % of LB (HER2+)-type cases were low Ki67-LI.

Conclusions

Our study demonstrates that all LA-type cases and most HG1 of LB (HER2+)-type cases are low proliferative. However, HG was not informative enough for estimating tumor proliferation in cases of LB (HER2−), HER2 and TN types. It is necessary to add other proliferation tools such as the gene expression profiling tool and Ki67-LI except in LA and HG1 of LB (HER2+)-type cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.

    CAS  PubMed  Google Scholar 

  2. de Azambuja E, Cardoso F, de Castro G, Colozza M Jr, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504–13.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.

    Article  CAS  PubMed  Google Scholar 

  6. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  CAS  PubMed  Google Scholar 

  7. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labeling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat. 2011;127:591–9.

    Article  CAS  PubMed  Google Scholar 

  8. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, South Sweden Breast Cancer Group. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol. 2010;23:251–9.

    Article  CAS  PubMed  Google Scholar 

  9. Rosa FE, Caldeira JR, Felipes J, Bertonha FB, Quevedo FC, Domingues MA, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol. 2008;39:720–30.

    Article  CAS  PubMed  Google Scholar 

  10. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, et al. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer. 2005;41:2924–34.

    Article  CAS  PubMed  Google Scholar 

  11. Dai J, Jian J, Bosland M, Frenkel K, Bernhardt G, Huang X. Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. Breast. 2008;17:172–9.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–904.

    CAS  PubMed  Google Scholar 

  13. Fasching PA, Heusinger K, Haberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Center, Asahikawa Medical University Hospital, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, 078-8510, Japan

    Satoshi Hayashi, Masahiro Kitada, Kazuhiro Sato, Yoshinari Matsuda, Kei Ishibashi & Satoshi Hirata

  2. Department of Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan

    Kensuke Oikawa & Naoyuki Miyokawa

Authors
  1. Satoshi Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Kitada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinari Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kei Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kensuke Oikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoyuki Miyokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Hayashi.

About this article

Cite this article

Hayashi, S., Kitada, M., Sato, K. et al. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers. Breast Cancer 21, 47–51 (2014). https://doi.org/10.1007/s12282-012-0353-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-012-0353-2

Keywords

Search

Navigation